915201-19-3

Upstream product

• 91312-53-7 ethyl (3R,5S)-5,6-O-isopropylidene-3,5,6-trihydroxyhexanoate 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 86030-94-6 methyl 3-O-(tert-butyldiphenylsilyl)-2,4-dideoxy-β-D-erythro-hexopyranoside 
• 915201-15-9 ethyl (3R,5S)-3-tert-butyldiphenylsilyloxy-5,6-(isopropylidenedioxy)hexanoate 
• 915201-17-1 (2S,4R,6S)-2-(p-chlorobenzenesulfonyloxy)methyl-4-tert-butyldiphenylsilyloxy-6-methoxytetrahydropyran 
• 915201-16-0 (3R,5S)-3-tert-butyldiphenylsilyloxy-5,6-(isopropylidenedioxy)hexanal 
• 915201-18-2 (2R,4R,6R)-4-tert-butyldiphenylsilyloxy-2-cyanomethyl-6-methoxytetrahydropyran 

Relevant academic research and scientific papers

Highly stereoselective hydrogenations-as key-steps in the total synthesis of statins

Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMG-CoA reductase) and became the standard of care for treatment of hypercholesterolemia because of their efficacy, safety, and long-term benefits. They are administered as diaste

Synthesis of the chiral side chain of statins - Lactone versus lactol pathway

4-O-Protected (4R,6S)-4-hydroxy-6-(hydroxymethyl)tetrahydropyran-2-ones (3) derived from enantiomerically pure (3R,5S)-3-hydroxy-5,6-(isopropylidenedioxy) hexanoates (2) are frequently considered as pivotal intermediates for the synthesis of pharmacologic

METHOD FOR THE PRODUCTION OF STATINS

The invention relates to a method for producing statins known as HMG-CoA reductase inhibitors. Some of the intermediate compounds used in the inventive method are novel compounds. The invention also relates to said novel intermediate compounds.